600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions
This study has been completed.
Sponsor:
Teva Pharmaceuticals USA
Information provided by:
Teva Pharmaceuticals USA
ClinicalTrials.gov Identifier:
NCT00840840
First received: February 6, 2009
Last updated: July 8, 2009
Last verified: July 2009
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess the bioequivalence between Amoxicillin/Clavulanate Potassium Oral Suspension 600/42.9 mg/5 mL and Augmentin ES-600 Oral Suspension, 600/42.9 mg/5 mL in healthy, male and female subjects, under fed conditions.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Drug: Augmentin ES-600™ |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Bio-equivalence Study Intervention Model: Crossover Assignment Masking: Open Label |
| Official Title: | An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects, Under Fed Conditions |
Resource links provided by NLM:
Further study details as provided by Teva Pharmaceuticals USA:
Primary Outcome Measures:
- Bioequivalence Based on Cmax for Amoxicillin [ Time Frame: Blood samples collected over 14 hour period ] [ Designated as safety issue: No ]
- Bioequivalence Based on AUC0-Inf for Amoxicillin [ Time Frame: Blood samples collected over 14 hour period ] [ Designated as safety issue: No ]
- Bioequivalence Based on AUC0-t for Amoxicillin [ Time Frame: Blood samples collected over 14 hour period ] [ Designated as safety issue: No ]
- Bioequivalence Based on Cmax for Clavulanic Acid [ Time Frame: Blood samples collected over 14 hour period ] [ Designated as safety issue: No ]
- Bioequivalence Based on AUC0-Inf for Clavulanic Acid [ Time Frame: Blood samples collected over 14 hour period ] [ Designated as safety issue: No ]
- Bioequivalence Based on AUC0-t for Clavulanic Acid [ Time Frame: Blood samples collected over 14 hour period ] [ Designated as safety issue: No ]
| Enrollment: | 48 |
| Study Start Date: | August 2002 |
| Study Completion Date: | August 2002 |
| Primary Completion Date: | August 2002 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL
1 x 600 mg/42.9 mg/5 mL, single-dose fasting
|
| Active Comparator: 2 |
Drug: Augmentin ES-600™
1 x 600 mg/42.9 mg/5 mL, single-dose fasting
|
Detailed Description:
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy, non-smoking male or non-pregnant, non-lactating female subjects, 18 years of age and over.
- Body weight within ±15% of the appropriate weight range published in 1993 by Metropolitan Life Insurance Company, Statistical Bureau and body-mass index (BMI) less than 30.
Negative for:
- HIV
- Hepatitis B and C
- Urine drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
- Cotinine (urine test)
- Breath alcohol (Breathalyzer)
- HCG (females only)
- No significant diseases or clinically significant abnormal laboratory values.
- No clinically significant findings in the physical examination.
- No clinically significant findings in vital sign measurements and 12-lead electrocardiogram (ECG).
- Informed of the nature of the study and give written consent prior to receiving any study medication.
- Female subjects: surgically steril, post-menopausal or practicing a recognized safe method of contraception (abstention, oral or implanted contraceptives, intra-uterine device or consistent condom plus spermicide use).
Exclusion Criteria:
- Known history or presence of any disease or condition which might compromise the following body systems: immunologic, endocrine, renal, cardiovascular, respiratory, hematologic, gastrointestinal, neurologic, hepatic, psychiatric or dermatologic
- More specifically: history or presence of significant: sensitivity to multiple allergens, diarrhea, stomach or intestinal disease, mononucleosis, renal or hepatic dysfunction and asthma.
- Known or suspected carcinoma.
Known history or presence of:
- Hypersensitivity or idiosyncratic reaction to amoxicillin, clavulanic acid, penicillin, cephalosporins and/or any other β-lactamase inhibitors.
- Clavulin-associated jaundice/hepatic dysfunction.
- Alcoholism within last 12 months.
- Drug dependence and/or substance abuse.
- Use of tobacco or nicotine-containing products, within last 12 months.
- On a special diet within 4 weeks prior to drug administration (i.e. a deliberate change in diet for any reason).
- Participation in another clinical trial or received an investigational product in the previous 30 days prior to drug administration.
- Donation up to 250 mK of blood in the previous 30 days, 251-500 mKL in the previous 45 days, 501-750 mL in the previous 60 days or above 750 mL in the previous 90 days prior to study start.
- Requirement of any medication, (prescription and/or over-the-counter) or dietary supplements on a routine basis, with the exception of occasional use of acetaminophen and oral or implanted contraceptives.
- Difficulty fasting or consuming the standard prescribed meals.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00840840
Locations
| Canada, Ontario | |
| Pharma Medica Research Inc. | |
| Toronto, Ontario, Canada, M1R 5A3 | |
Sponsors and Collaborators
Teva Pharmaceuticals USA
Investigators
| Principal Investigator: | Xueyu (Eric) Chen, M.D., Ph.D. | Pharma Medica Research |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00840840 History of Changes |
| Other Study ID Numbers: | 02-544 |
| Study First Received: | February 6, 2009 |
| Results First Received: | May 18, 2009 |
| Last Updated: | July 8, 2009 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Teva Pharmaceuticals USA:
|
Bioequivalence Healthy Subjects |
Additional relevant MeSH terms:
|
Amoxicillin Amoxicillin-Potassium Clavulanate Combination Clavulanic Acids Clavulanic Acid Anti-Bacterial Agents |
Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 17, 2013